One in five teenagers in the U.S. is afflicted with obesity and the prevalence continues to rise. That statistic could now change after research spearheaded by a University of Minnesota Medical School professor led to the approval of the first anti-obesity medication for adolescents in the U.S. in over 17 years.
The U.S. Food and Drug Administration (FDA) approved an updated label for liraglutide (Saxenda®) injection 3.0 milligrams for use in the treatment of obesity in adolescents between the ages of 12 and 17 with a body weight above 60 kilograms (or 132 pounds) and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults. The treatment will be used as an adjunct to reduced-calorie meals and increased physical activity.
Aaron S. Kelly, PhD, professor in the Department of Pediatrics and co-director of the Center for Pediatric Obesity Medicine at the U of M Medical School, was the international principal investigator and served as the signatory author for the phase 3 clinical trial that led to FDA approval. The study was published earlier this year in the New England Journal of Medicine and presented at Endo 2020, the Endocrine Societ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).